These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28971318)

  • 1. Preferences for multigene panel testing for hereditary breast cancer risk among ethnically diverse BRCA-uninformative families.
    Vicuña B; Delaney HD; Flores KG; Ballinger L; Royce M; Dayao Z; Pal T; Kinney AY
    J Community Genet; 2018 Jan; 9(1):81-92. PubMed ID: 28971318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors Associated with Interest in Gene-Panel Testing and Risk Communication Preferences in Women from BRCA1/2 Negative Families.
    Flores KG; Steffen LE; McLouth CJ; Vicuña BE; Gammon A; Kohlmann W; Vigil L; Dayao ZR; Royce ME; Kinney AY
    J Genet Couns; 2017 Jun; 26(3):480-490. PubMed ID: 27496122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
    Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
    Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of mutations in a diverse cohort of 3162 women tested via the same multigene cancer panel in a managed care health plan.
    Alvarado M; Tiller GE; Chung J; Haque R
    J Community Genet; 2020 Jul; 11(3):359-366. PubMed ID: 32096056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions.
    Su Y; Yao Q; Xu Y; Yu C; Zhang J; Wang Q; Li J; Shi D; Yu B; Zeng Y; Zhu X; Bai Q; Zhou X
    Front Genet; 2021; 12():674094. PubMed ID: 34917121
    [No Abstract]   [Full Text] [Related]  

  • 6. Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer.
    Elsayegh N; Webster RD; Gutierrez Barrera AM; Lin H; Kuerer HM; Litton JK; Bedrosian I; Arun BK
    Cancer Med; 2018 Jun; 7(6):2718-2726. PubMed ID: 29733510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Communication of BRCA results and family testing in 1,103 high-risk women.
    Cheung EL; Olson AD; Yu TM; Han PZ; Beattie MS
    Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2211-9. PubMed ID: 20699375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
    Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
    Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors.
    Cragun D; Weidner A; Lewis C; Bonner D; Kim J; Vadaparampil ST; Pal T
    Cancer; 2017 Jul; 123(13):2497-2505. PubMed ID: 28182268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast Cancer Risk Perceptions among Relatives of Women with Uninformative Negative BRCA1/2 Test Results: The Moderating Effect of the Amount of Shared Information.
    Himes DO; Clayton MF; Donaldson GW; Ellington L; Buys SS; Kinney AY
    J Genet Couns; 2016 Apr; 25(2):258-69. PubMed ID: 26245632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics affect the impact of an uninformative DNA test result: the course of worry and distress experienced by women who apply for genetic testing for breast cancer.
    van Dijk S; Timmermans DR; Meijers-Heijboer H; Tibben A; van Asperen CJ; Otten W
    J Clin Oncol; 2006 Aug; 24(22):3672-7. PubMed ID: 16877736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a novel pathogenic variant in
    Laraqui A; Cavaillé M; Uhrhammer N; ElBiad O; Bidet Y; El Rhaffouli H; El Anaz H; Rahali DM; Kouach J; Guelzim K; Badaoui B; AlBouzidi A; Oukabli M; Tanz R; Sbitti Y; Ichou M; Ennibi K; Sekhsokh Y; Bignon YJ
    J Genomics; 2021; 9():43-54. PubMed ID: 34646395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implication and Influence of Multigene Panel Testing with Genetic Counseling in Korean Patients with BRCA1/2 Mutation-Negative Breast Cancer.
    Park JS; Shin S; Lee YJ; Lee ST; Nam EJ; Han JW; Lee SH; Kim TI; Park HS
    Cancer Res Treat; 2022 Oct; 54(4):1099-1110. PubMed ID: 34793666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel.
    Moran O; Nikitina D; Royer R; Poll A; Metcalfe K; Narod SA; Akbari MR; Kotsopoulos J
    Breast Cancer Res Treat; 2017 Jan; 161(1):135-142. PubMed ID: 27798748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients.
    Culver JO; Ricker CN; Bonner J; Kidd J; Sturgeon D; Hodan R; Kingham K; Lowstuter K; Chun NM; Lebensohn AP; Rowe-Teeter C; Levonian P; Partynski K; Lara-Otero K; Hong C; Morales Pichardo J; Mills MA; Brown K; Lerman C; Ladabaum U; McDonnell KJ; Ford JM; Gruber SB; Kurian AW; Idos GE
    Cancer; 2021 Apr; 127(8):1275-1285. PubMed ID: 33320347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the appropriate genetic testing criteria for breast cancer in the Chinese population?-Analysis of genetic and clinical features from a single cancer center database.
    Ni M; Wang F; Yang A; Shao Q; Xue C; Xia W; Xu F; Lin X; Huang J; Bi X; Hong R; Chen M; Zheng Q; Jiang K; Xie X; Tang J; Wang X; Yuan Z; Wang S; Shi Y; An X
    Cancer Med; 2023 Jun; 12(12):13019-13030. PubMed ID: 37096751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
    Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L
    Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of germline pathogenic variants in breast cancer predisposition genes among young Turkish breast cancer patients.
    Isiklar AD; Aliyeva L; Yesilyurt A; Soyder A; Basaran G
    Breast Cancer Res Treat; 2023 Nov; 202(2):297-304. PubMed ID: 37615792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.